Furthermore, IL-8 is not only an important clinical marker of progression, but also a biomarker to monitor the clinical benefit of ICI, since early decrease in IL-8 indicated response to ICI therapy in melanoma patients and unmasked true response in cancer patients showing pseudoprogression (36). The gene discussed is CXCL8; the disease is cancer.